ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,805 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentZugCRISPR Therapeutics AG
CRISPR Therapeutics AG Logo
Verified· 2 sources

CRISPR Therapeutics AG

Summary

About the company

The core activity of CRISPR Therapeutics is the development of gene therapeutic medicines, particularly through the application of CRISPR-Cas9 technology, to cure diseases at the molecular level. The company focuses on developing medicines for various diseases such as sickle cell anemia, β-thalassemia, cancer, autoimmune disorders, and regenerative medicine.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
Pharmaceutical Industry
✓ Offered6
CRISPR/Cas9 gene editing therapies
CRISPR/Cas9-based gene editing therapies for the treatment of severe diseases; ex vivo and in vivo programmes for genetic disorders and cell therapies.
Approved CRISPR-based therapy (CASGEVY™)
CASGEVY™ (exagamglogene autotemcel), an approved CRISPR/Cas9 gene-edited therapy for certain patients with sickle cell disease or transfusion-dependent β-thalassemia.
Treatments for hemoglobinopathies
Gene-edited blood stem cell therapies for sickle cell disease and β-thalassemia; the goal is to activate fetal hemoglobin and, with the next generation, to enable in vivo editing.
CAR T-cell therapies for oncology and autoimmune diseases
Gene-edited allogeneic CAR T-cell therapies for CD19+ malignancies and autoimmune diseases; off-the-shelf approaches with multiplex edits to improve potency, persistence and safety.
In vivo gene editing therapies
In vivo gene editing programmes using lipid nanoparticles or viral vectors to treat cardiovascular, muscle, lung and CNS diseases.

Knowledge

No knowledge articles yet

Once CRISPR Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

CRISPR Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank CRISPR Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of CRISPR Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Baarerstrasse 14
6300 Zug

At a glance

Legal form
Corporation
UID
CHE-494.642.722
Founded
2013 · 13 years
Last commercial register change
June 11, 2026
Employees
101 to 500

Similar companies

QA
Qualitas AG
Zug
3D
3 D AG
Baar
SC
Swiss Cardio Technologies AG
Rotkreuz
AT
AI2C Technologies AG
Cham